Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – Here’s What Happened

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s stock price gapped up prior to trading on Tuesday. The stock had previously closed at $14.35, but opened at $15.13. Astellas Pharma shares last traded at $14.44, with a volume of 1,259 shares changing hands.

Wall Street Analyst Weigh In

Separately, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy”.

Astellas Pharma Stock Performance

The stock has a fifty day simple moving average of $14.75 and a two-hundred day simple moving average of $14.45. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.93 and a current ratio of 1.20. The stock has a market cap of $25.97 billion, a price-to-earnings ratio of 10.92 and a beta of 0.08.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines for patients worldwide. Its portfolio focuses on areas of significant unmet medical need, including oncology, immunology, urology, ophthalmology, neuroscience and medical conditions related to genetic regulation.

The company’s products include XTANDI (enzalutamide) for certain prostate cancers, XOSPATA (gilteritinib) for acute myeloid leukemia, PADCEV (enfortumab vedotin-ejfv) for certain urothelial cancers, and PROGRAF (tacrolimus), an immunosuppressant used primarily to help prevent organ rejection following transplantation.